GHRP-2 vs GHRP-6: Potency vs Hunger Compared

Both peptides are six-amino-acid agonists of the ghrelin receptor (GHS-R1a), the same receptor your stomach's hunger hormone activates. Think of that receptor as a doorbell wired to two rooms: the pituitary's GH room and the brain's appetite room. GHRP-6 rings both rooms at full volume. GHRP-2 rings the GH room louder and the appetite room softer.

That is the analogy. The literal version: both peptides trigger pulsatile GH release from the pituitary, and both stimulate appetite through ghrelin mimicry, but GHRP-2 delivers more GH per microgram while GHRP-6 delivers a stronger, faster hunger signal. Neither shuts down your natural production the way synthetic HGH does, because both work upstream of the pituitary.

Strip away the marketing and four real differences separate these peptides.

Potency. GHRP-2 wins on raw GH output. If the research goal is maximum GH pulse per injection, GHRP-2 is the stronger tool at the same microgram dose.

Hunger. This is the fork in the road. GHRP-6 produces intense, reliable hunger; GHRP-2 produces a milder version of the same effect. Milder does not mean absent: infused GHRP-2 increased food intake by 35.9% in healthy men, with every single subject eating more (Laferrère et al., J Clin Endocrinol Metab, 2005). If any appetite stimulation is unacceptable, ipamorelin is the cleaner choice.

Cortisol and prolactin. Both peptides nudge ACTH, cortisol, and prolactin upward. Arvat's team measured GHRP-2 head-on in humans: GH rose dramatically while prolactin, ACTH, and cortisol rose modestly and transiently (Arvat et al., Peptides, 1997). At 100 mcg doses these rises stay small; push to 300-600 mcg and they become measurable enough to matter for long protocols.

Use-case history. GHRP-2 carries a diagnostic approval in Japan and pediatric testing history. GHRP-6 carries 35 years of human research data but no approval anywhere.

The dosing math is nearly identical because both peptides saturate the ghrelin receptor around the same point. Roughly 100 mcg produces close to the maximum GH pulse; doses beyond ~300 mcg add side effects faster than GH.

Timing rules matter more than the microgram count. Carbohydrates and fats blunt the GH pulse, so inject on an empty stomach and wait at least 20-30 minutes before eating. The pre-bed injection rides your natural nocturnal GH pulse, which also supports sleep-related recovery.

The one strategic difference: GHRP-6 users often time injections 30 minutes before a scheduled meal, turning the hunger side effect into a feeding tool. GHRP-2 users generally dose for GH output alone. For vial math, use our peptide reconstitution calculator, and cross-check doses against the peptide dosage chart.

Match the peptide to the primary research goal, then let everything else follow.

Appetite and bulking phases: GHRP-6. If the limiting factor is eating enough, GHRP-6's hunger effect is a feature. Underweight subjects and hard gainers in research settings get a GH pulse plus a reliable appetite signal in one injection. Details in the GHRP-6 guide.

Maximum GH output and recomposition: GHRP-2. When the goal is the biggest GH pulse per injection with hunger as tolerable background noise, GHRP-2 wins on potency. During a fat-loss phase, its milder appetite effect is easier to work around than GHRP-6's.

No hunger, no cortisol, no prolactin: neither. Ipamorelin activates the same receptor with near-zero effect on appetite, cortisol, or prolactin, at the cost of a somewhat smaller GH pulse. Our MK-677 vs ipamorelin and tesamorelin vs ipamorelin comparisons map the cleaner alternatives.

Clinical-grade evidence: look elsewhere. Both GHRPs stalled before Phase III. Tesamorelin and sermorelin carry stronger regulatory footing; the CJC-1295 vs sermorelin comparison covers that tier.

Neither GHRP is typically run alone. The reason is receptor synergy documented since 1990: a GHRP plus a GHRH analog releases more GH together than the sum of either alone (Bowers et al., J Clin Endocrinol Metab, 1990). The two signals hit the pituitary through different receptors at the same moment.

The standard research pairing is 100 mcg of either GHRP with 100 mcg of CJC-1295 without DAC, injected together 1-3x daily. The CJC-1295 dosage guide covers the GHRH side of the stack. The with-DAC version changes the logic entirely: its 6-8 day half-life creates a continuous GH bleed rather than pulses, explained in the CJC-1295 with DAC guide.

GHRP choice within the stack follows the same fork as before. GHRP-6 plus CJC-1295 suits mass phases where the hunger helps. GHRP-2 plus CJC-1295 suits recomposition goals, though many researchers gravitate toward the better-characterized CJC-1295 and ipamorelin pairing instead. Plan combined doses with the CJC-1295/ipamorelin dosage calculator.

Both peptides are well tolerated at saturation doses in published human studies, with no serious adverse events reported at 100 mcg. The differences show up in degree, and in what happens when doses climb.

Two scenarios show how dosing errors play out. First: a researcher doses 300 mcg of GHRP-6 at bedtime on an empty stomach, expecting sleep. The hunger lands 25 minutes later and either keeps them awake or sends them to the kitchen for 800 unplanned calories, undoing a cutting week in one snack. The fix is dosing GHRP-6 about 90 minutes before a planned meal and reserving pre-bed injections for GHRP-2.

Second: a researcher triples GHRP-2 to 600 mcg chasing a bigger pulse. GH output barely rises past the ~100 mcg saturation point, but prolactin and cortisol climb measurably at supraphysiological doses (Arvat et al., Peptides, 1997). Weeks of that pattern invite fluid retention and mood effects with no added benefit. The fix is staying at 100-150 mcg and adding a second daily injection instead of a bigger one.

Long-term GH-axis caveats apply to both: monitor IGF-1, watch fasting glucose, and avoid all GH secretagogues with any active malignancy. The peptide safety guide covers screening in detail.